Nirsevimab for Prevention of Hospitalizations Due to RSV in Infants
Infants at risk for respiratory syncytial virus (RSV)–associated lower respiratory tract infection responded positively to nirsevimab, a pragmatic study shows, with reduced hospitalizations for RSV-associated